Capricor Therapeutics | CAPR - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Bioline Rx USD 343K 111K 2025-09
Capricor Therapeutics 11.13M 8.87M 2024-12
Cipla INR 39.1B 2.54B 2026-03
Cytokinetics USD 19.2M 1.44M 2026-03
Geron USD 50.14M 3.44M 2026-03
Grifols EUR 766.49M 39.74M 2024-12
Immunic 0 0 2025-03
J&J USD 17.24B 642M 2026-03
Plus Therapeutics 1.37M 30K 2025-12
Prothena USD 21K 2.39M 2025-12
PTC Therapeutics USD 232.94M 84.56M 2026-03
Sarepta Therapeutics USD 621.34M 577.79M 2026-03